You're asking about a specific chemical compound, **2-(2,3-dimethylphenoxy)-N-(2-oxo-1-benzopyran-6-yl)acetamide**. This is a complex organic molecule with a long and descriptive name!
**Understanding the structure:**
* **2-(2,3-dimethylphenoxy):** This part indicates a phenoxy group (an oxygen atom attached to a benzene ring) with two methyl groups (CH3) at positions 2 and 3 on the benzene ring.
* **N-(2-oxo-1-benzopyran-6-yl):** This part describes an amide group (NHCO) attached to a benzopyran ring (a fused ring system of benzene and pyran). The 2-oxo indicates a ketone group (C=O) at position 2 of the benzopyran ring, and the -yl ending indicates it's attached to the nitrogen atom.
* **Acetamide:** The final part simply indicates that the molecule contains an acetamide group (CH3CONH).
**Importance for Research:**
It's difficult to say definitively why this specific compound is important for research without more context. However, based on its structure, it's likely to be a potential:
* **Drug candidate:** This compound exhibits a mix of structural features that are commonly seen in drug molecules. The phenoxy and benzopyran rings can act as pharmacophores (parts of the molecule that bind to a specific biological target). The acetamide group is often used in drug design to improve solubility and bioavailability.
* **Chemical probe:** The unique structure could make this compound useful for studying specific biological processes. It might act as an inhibitor or activator of certain enzymes, receptors, or other molecular targets.
* **Building block for synthesis:** The compound itself might not be the target of study, but it could serve as a starting material for synthesizing other molecules with interesting properties.
**To get more information on the research significance of this specific compound:**
1. **Search scientific databases:** Try searching for the compound's name in databases like PubMed, SciFinder, or Reaxys. Look for publications that mention it.
2. **Look for patents:** This compound might be mentioned in patents, which can provide information about its potential uses and applications.
3. **Contact experts:** If you know any researchers in the field of organic chemistry or drug discovery, they might be able to shed light on the compound's importance.
Remember, research is an ongoing process, and new discoveries about the properties and applications of chemical compounds are constantly being made.
ID Source | ID |
---|---|
PubMed CID | 965764 |
CHEMBL ID | 1491735 |
CHEBI ID | 109585 |
Synonym |
---|
2-(2,3-dimethyl-phenoxy)-n-(2-oxo-2h-chromen-6-yl)-acetamide |
BAS 08208036 |
smr000612714 |
MLS001219462 |
2-(2,3-dimethylphenoxy)-n-(2-oxo-2h-chromen-6-yl)acetamide |
STK336984 |
CHEBI:109585 |
AKOS000468130 |
2-(2,3-dimethylphenoxy)-n-(2-oxochromen-6-yl)acetamide |
HMS2889M15 |
CHEMBL1491735 |
sr-01000364834 |
SR-01000364834-1 |
2-(2,3-dimethylphenoxy)-n-(2-oxo-1-benzopyran-6-yl)acetamide |
Q27188729 |
Class | Description |
---|---|
coumarins | |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASE | Homo sapiens (human) | Potency | 75.1930 | 0.0032 | 45.4673 | 12,589.2998 | AID2517 |
euchromatic histone-lysine N-methyltransferase 2 | Homo sapiens (human) | Potency | 50.1187 | 0.0355 | 20.9770 | 89.1251 | AID504332 |
histone-lysine N-methyltransferase 2A isoform 2 precursor | Homo sapiens (human) | Potency | 3.9811 | 0.0103 | 23.8567 | 63.0957 | AID2662 |
geminin | Homo sapiens (human) | Potency | 29.0929 | 0.0046 | 11.3741 | 33.4983 | AID624296 |
Rap guanine nucleotide exchange factor 4 | Homo sapiens (human) | Potency | 112.2020 | 3.9811 | 46.7448 | 112.2020 | AID720711 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Process | via Protein(s) | Taxonomy |
---|---|---|
guanyl-nucleotide exchange factor activity | Rap guanine nucleotide exchange factor 4 | Homo sapiens (human) |
protein binding | Rap guanine nucleotide exchange factor 4 | Homo sapiens (human) |
cAMP binding | Rap guanine nucleotide exchange factor 4 | Homo sapiens (human) |
protein-macromolecule adaptor activity | Rap guanine nucleotide exchange factor 4 | Homo sapiens (human) |
small GTPase binding | Rap guanine nucleotide exchange factor 4 | Homo sapiens (human) |
[Information is prepared from geneontology information from the June-17-2024 release] |
Process | via Protein(s) | Taxonomy |
---|---|---|
cytosol | Rap guanine nucleotide exchange factor 4 | Homo sapiens (human) |
plasma membrane | Rap guanine nucleotide exchange factor 4 | Homo sapiens (human) |
membrane | Rap guanine nucleotide exchange factor 4 | Homo sapiens (human) |
hippocampal mossy fiber to CA3 synapse | Rap guanine nucleotide exchange factor 4 | Homo sapiens (human) |
plasma membrane | Rap guanine nucleotide exchange factor 4 | Homo sapiens (human) |
[Information is prepared from geneontology information from the June-17-2024 release] |
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (20.00) | 29.6817 |
2010's | 3 (60.00) | 24.3611 |
2020's | 1 (20.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.56) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 5 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |